ReviewEndocrinology and metabolism clinics of North America2019
Genetic-guided Risk Assessment and Management of Thyroid Cancer.
Review in Endocrinology and metabolism clinics of North America, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed.
- Sex and Mortality Among Patients with Papillary Thyroid Cancer.JAMA network open · 2026Article
- Article
- Highly sensitive profiling somatic mutations of thyroid cancer by nucleotide-enrichment-based MALDI-TOF MS assay.Scientific reports · 2026Article
- ARMS-qPCR-Based Detection of BRAF and TERT Promoter Mutations: A Cost-Effective Strategy for Molecular Diagnosis of Papillary Thyroid Carcinoma.International journal of endocrinology · 2026Article
- BRAF V600E in thyroid cancer: navigating prognostic uncertainty and therapeutic opportunity.European thyroid journal · 2025Review
- Dose-Response Relationship Between BRAF V600E Abundance and Cervical Lymph Node Metastasis in Papillary Thyroid Cancer.Cancers · 2025Article
- Predicting multigenic co-mutations in differentiated thyroid cancer using contrast-enhanced ultrasonography: model development and internal validation.Ultrasonography (Seoul, Korea) · 2025Article
- Genetic modification of the AJCC classification of papillary thyroid cancer: an international, multicentre, retrospective cohort study.The Lancet. Oncology · 2025Article
- Telomeres, telomerase, and cancer: mechanisms, biomarkers, and therapeutics.Experimental hematology & oncology · 2025Review
- Cytologically non-malignant thyroid nodules with three or more high-risk genetic mutations have poor outcomes.Endocrine oncology (Bristol, England) · 2025Article
- Biomarkers in Thyroid Cancer: Emerging Opportunities from Non-Coding RNAs and Mitochondrial Space.International journal of molecular sciences · 2024Review
- Genetic trio of BRAF and TERT alterations and rs2853669TT in papillary thyroid cancer aggressiveness.Journal of the National Cancer Institute · 2024Article
- US of thyroid nodules: can AI-assisted diagnostic system compete with fine needle aspiration?European radiology · 2024Article
- Dynamic risk assessment in patients with differentiated thyroid cancer.Reviews in endocrine & metabolic disorders · 2024Review
- Prediction of cytology-histology discrepancy when Bethesda cytology reports benign results for thyroid nodules in women: with special emphasis on pregnancy.The Libyan journal of medicine · 2023Article
- Is There a Role for Molecular Testing for Low-Risk Differentiated Thyroid Cancer? A Cost-Effectiveness Analysis.Cancers · 2023Article
- Comparison of surgical strategies in the treatment of low-risk differentiated thyroid cancer.BMC endocrine disorders · 2023Article
- An integrative analysis of the tumor suppressors and oncogenes from sexual dimorphism and gene expression alteration features in thyroid cancer.Cancer biomarkers : section A of Disease markers · 2023Article
- Clinical and prognosis value of the number of metastatic lymph nodes in patients with papillary thyroid carcinoma.BMC surgery · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Controversies exist on how to optimally manage thyroid cancer because the prognosis is often uncertain based on clinical backgrounds. This can now be helped with prognostic genetic markers in thyroid cancer, exemplified by BRAF V600E and TERT promoter mutations, which have been well characterized and widely appreciated. The genetic duet of BRAF V600E/RAS and TERT promoter mutations is a most robust prognostic genetic pattern for poor prognosis of differentiated thyroid cancer. The high negative predictive values of the prognostic genetic markers are equally valuable. The best prognostic value of genetic markers in thyroid cancer is achieved through a clinical risk level-based and genotype-individualized manner.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.